Source: Annual Congress 2005 - Resistant and MDR tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. Karagoz, P. Pazarli, D. Yetis Duman, G. Akel, O. Yazicioglu (Istanbul, Turkey). Prevalance of initial and acquired resistance to antituberculosis drugs in our clinic. Eur Respir J 2005; 26: Suppl. 49, 4136

Member's Comments

No comment yet.

Related content which might interest you: Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Investigating trends in antituberculosis (anti-TB) drug resistance among treated patients of a university respiratory infections unit in Greece Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007 A Cuban successful history on antituberculosis treatment and drug resistance surveillance Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002 Primary and acquired drug resistance in childhood tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 653s Year: 2005 Medico-social features of resistance development to new anti–TB drugs in patients with MDR/XDR TB Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 The association between HIV and antituberculosis drug resistance Source: Eur Respir J 2008; 32: 718-725 Year: 2008 Antituberculous drug resistance rates in soldier patients newly diagnosed with TB in Turkey Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Antituberculosis drug resistance rates in patients newly diagnosed with TB in Istanbul Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Spreading of resistance to group A anti-tuberculosis drugs among TB patients in Astana city Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Increasing anti-tuberculosis drug resistance in the UK Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 First-line anti-TB drug resistance pattern and its trend in the national TB referral center in Iran Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008